Inactive Instrument

New York Global Innovations Inc Stock Other OTC

Equities

US45727E1064

End-of-day quote Other OTC Other stock markets
- ^USD	-

2023	Manuka, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Manuka, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Financials (USD)

Sales 2021	0.01	Sales 2022	0.31	Capitalization	130M
Net income 2021	-	Net income 2022	-1M	EV / Sales 2021 *	-
Net cash position 2021	78.02K	Net Debt 2022	301K	EV / Sales 2022	418,843,518 x
P/E ratio 2021 *	-	P/E ratio 2022	-48.8 x	Employees	-
Yield 2021 *	-	Yield 2022	-	Free-Float	0%

More Fundamentals * Assessed data

Latest news about New York Global Innovations Inc

Manuka, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 21	CI
Manuka, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-15	CI
Manuka, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-18	CI
Artemis Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Artemis Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	23-03-30	CI
Artemis Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Artemis Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-22	CI
Artemis Therapeutics Inc. Announces Executive Changes	22-07-26	CI
Manuka Ltd completed the acquisition of Artemis Therapeutics Inc. in a reverse merger transaction.	22-06-29	CI
Artemis Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-23	CI
Manuka Ltd entered into a share exchange agreement to acquire Artemis Therapeutics Inc. for $92.4 million in a reverse merger transaction.	22-03-08	CI
Artemis Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-03	CI
Artemis Therapeutics Inc. Auditor Raises 'Going Concern' Doubt	22-03-02	CI
Artemis Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-10	CI
Artemis Therapeutics Inc. Issues Two Unsecured Promissory Notes	21-11-08	CI

More news

Press releases New York Global Innovations Inc

Manuka Announces Review of Strategic Alternatives	Nov. 16	GL
ARTEMIS THERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.	23-05-03	AQ
ARTEMIS THERAPEUTICS, INC. - 10-K/A - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.	23-04-06	AQ
ARTEMIS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	23-03-31	AQ
ARTEMIS THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	22-11-14	AQ

More press releases

Managers and Directors - New York Global Innovations Inc

Managers	Title	Age	Since
Shimon Citron CEO	Chief Executive Officer	70	22-06-29
David Dana DFI	Director of Finance/CFO	60	22-07-25
Dana Wolf CTO	Chief Tech/Sci/R&D Officer	66	16-08-01

Members of the board	Title	Age	Since
Shimon Citron CEO	Chief Executive Officer	70	22-06-29

More insiders

Company Profile

Artemis Therapeutics, Inc. is a shell company. The Company has not commenced any operating business. The Company has not generated revenues.

Sector

More about the company